Global Personalized Cancer Vaccines Market Opportunity, Clinical Innovation, Development Technology Platforms & Clinical Trials Insight 2031
Report Findings & Highlights:
Personalized cancer vaccines have emerged as a significant area of next generation cancer immunotherapy, driven by increasing interest in therapeutic approaches tailored to the unique molecular characteristics of individual tumors. Differing from traditional cancer vaccines, which are based on tumor associated antigens, personalized vaccines are focused on particular patient mutations and neoantigens. Due to advancements in genomic sequencing, AI-driven antigen prediction, mRNA technology, and personalized manufacturing, a significant increase in R&D activity has been observed across various indications of cancer. The market has moved beyond purely experimental stage, and some of the candidates, such as intismeran autogene, have reached Phase 3 clinical trials, while autogene cevumeran is already undergoing Phase 2 evaluation. Personalized cancer vaccine Provenge has shown its commercial success as the first approved by FDA personalized cancer vaccine.
This report offers an overall evaluation of the personalized cancer vaccine market that includes scientific basis, clinical developments, technological trends, competitive landscape, and commercialization possibilities. The review also analyzes the evolution of cancer vaccine approaches, the importance of neoantigen and human leukocyte antigen and the involvement of pharmacogenomic, prognostic, and predictive biomarkers in the development of individualized vaccines. Finally, the report examines Provenge as well as new personalized cancer vaccine products and assesses their clinical developments, treatment options, and commercialization opportunities. The report aims to provide guidance for pharmaceutical and biotechnology companies, investors, researchers, healthcare organizations, and any other stakeholder that may be interested in understanding the evolving landscape of personalized cancer vaccines.
Clinical Trials Insight Included In Report
The clinical development segment is one of the major segments in the market for personalized cancer vaccines, with growing research being conducted on various solid and hematological cancers. At present, the studies are assessing the efficacy of personalized cancer vaccines in the treatment of melanoma, lung cancer, gastrointestinal cancer (pancreatic cancer included), breast cancer, prostate cancer, gynecological cancer, brain cancer, and hematological cancer. The focus is being laid on the use of personalized cancer vaccines in combination with surgical resection of tumors for adjuvant therapy. In addition, combination treatments with immune checkpoint inhibitors are gaining popularity in clinical development.
The report provides insights on ongoing and concluded clinical trials, analyzing their important characteristics, such as type of cancer, vaccine platform, treatment setting, combination therapies, clinical endpoints, and development status. Clinical results from major programs for a longer period of time are also considered in order to give an overview of the recent evidence on personalized vaccines. The analysis reflects how the area of personalized vaccine has transformed from the stage of proving the concept to the stage of advanced clinical development.
Major Companies Involved In Personalized Cancer Vaccine R&D
In terms of personalized cancer vaccine, there is a number of pharmaceutical and biotech companies, as well as technology firms. Moderna and Merck are two of the most prominent companies involved in personalized cancer vaccine development thanks to intismeran autogene, the most advanced personalized cancer vaccine currently and the only one being assessed in Phase 3 trials. BioNTech has also managed to make a strong position thanks to its individualized neoantigen vaccine platform and their candidate, autogene cevumeran, that is under investigation in Phase 2.
Other companies that are making contributions in this sector include CureVac, Geneos Therapeutics, Genentech, TuHURA Biosciences, among others. They are taking different directions with regard to mRNA, peptide, viral vector, biomaterial and other types of vaccines using their platforms. Some examples of proprietary platforms that have been used to develop such vaccines include iNeST by BioNTech, mRNA Design Studio by Moderna, and myvac by Transgene. Partnerships among pharmaceutical companies, biotech companies, universities, and technology providers also continue to facilitate the growth of the market in terms of both clinical and platform development.
Future Outlook For Personalized Cancer Vaccines Market
The direction that the personalized cancer vaccine market is likely to take will involve clinical validation, expansion into other types of cancers, as well as developments in the areas of individualized vaccine design and manufacturing. Integration of whole genome and tumor sequencing with artificial intelligence is likely to increase the number of neoantigens identified for patients, while mRNA and other flexible vaccine platforms will allow the development of individualized vaccines in larger volumes.
In addition to that, personalized vaccines are expected to be increasingly used in conjunction with immunotherapies, especially immune checkpoint inhibitors. In addition, advances in biomarker development may facilitate patient selection for trials as well as improve the design of trials. The growing activity in North America, Europe, and Asia-Pacific shows that the field of personalized cancer vaccine development is becoming global. In summary, late-stage candidate development, the expansion of clinical trials, and the involvement of large pharma and biotech companies indicate that the personalized cancer vaccine space is becoming an increasingly important part of the changing cancer immunotherapy landscape.
- Currently Only 1 Vaccine Approved In Market: Provenge
- Next Commercial Approval Expected By 2031 For NSCL/Melanoma
- Pricing & Dosing Insight On Only Approved Personalized Cancer Vaccine
- Clinical Innovation Trends Outlook By Indication & Region
- Insight On Personalized Cancer Vaccines In Clinical Trials: > 20 Vaccines
- Personalized Cancer Vaccines Clinical Trials Insight By Developer, Indication & Phase
- Personalized Cancer Vaccines Proprietary Development Platforms Insight
- Competitive Landscape
Personalized cancer vaccines have emerged as a significant area of next generation cancer immunotherapy, driven by increasing interest in therapeutic approaches tailored to the unique molecular characteristics of individual tumors. Differing from traditional cancer vaccines, which are based on tumor associated antigens, personalized vaccines are focused on particular patient mutations and neoantigens. Due to advancements in genomic sequencing, AI-driven antigen prediction, mRNA technology, and personalized manufacturing, a significant increase in R&D activity has been observed across various indications of cancer. The market has moved beyond purely experimental stage, and some of the candidates, such as intismeran autogene, have reached Phase 3 clinical trials, while autogene cevumeran is already undergoing Phase 2 evaluation. Personalized cancer vaccine Provenge has shown its commercial success as the first approved by FDA personalized cancer vaccine.
This report offers an overall evaluation of the personalized cancer vaccine market that includes scientific basis, clinical developments, technological trends, competitive landscape, and commercialization possibilities. The review also analyzes the evolution of cancer vaccine approaches, the importance of neoantigen and human leukocyte antigen and the involvement of pharmacogenomic, prognostic, and predictive biomarkers in the development of individualized vaccines. Finally, the report examines Provenge as well as new personalized cancer vaccine products and assesses their clinical developments, treatment options, and commercialization opportunities. The report aims to provide guidance for pharmaceutical and biotechnology companies, investors, researchers, healthcare organizations, and any other stakeholder that may be interested in understanding the evolving landscape of personalized cancer vaccines.
Clinical Trials Insight Included In Report
The clinical development segment is one of the major segments in the market for personalized cancer vaccines, with growing research being conducted on various solid and hematological cancers. At present, the studies are assessing the efficacy of personalized cancer vaccines in the treatment of melanoma, lung cancer, gastrointestinal cancer (pancreatic cancer included), breast cancer, prostate cancer, gynecological cancer, brain cancer, and hematological cancer. The focus is being laid on the use of personalized cancer vaccines in combination with surgical resection of tumors for adjuvant therapy. In addition, combination treatments with immune checkpoint inhibitors are gaining popularity in clinical development.
The report provides insights on ongoing and concluded clinical trials, analyzing their important characteristics, such as type of cancer, vaccine platform, treatment setting, combination therapies, clinical endpoints, and development status. Clinical results from major programs for a longer period of time are also considered in order to give an overview of the recent evidence on personalized vaccines. The analysis reflects how the area of personalized vaccine has transformed from the stage of proving the concept to the stage of advanced clinical development.
Major Companies Involved In Personalized Cancer Vaccine R&D
In terms of personalized cancer vaccine, there is a number of pharmaceutical and biotech companies, as well as technology firms. Moderna and Merck are two of the most prominent companies involved in personalized cancer vaccine development thanks to intismeran autogene, the most advanced personalized cancer vaccine currently and the only one being assessed in Phase 3 trials. BioNTech has also managed to make a strong position thanks to its individualized neoantigen vaccine platform and their candidate, autogene cevumeran, that is under investigation in Phase 2.
Other companies that are making contributions in this sector include CureVac, Geneos Therapeutics, Genentech, TuHURA Biosciences, among others. They are taking different directions with regard to mRNA, peptide, viral vector, biomaterial and other types of vaccines using their platforms. Some examples of proprietary platforms that have been used to develop such vaccines include iNeST by BioNTech, mRNA Design Studio by Moderna, and myvac by Transgene. Partnerships among pharmaceutical companies, biotech companies, universities, and technology providers also continue to facilitate the growth of the market in terms of both clinical and platform development.
Future Outlook For Personalized Cancer Vaccines Market
The direction that the personalized cancer vaccine market is likely to take will involve clinical validation, expansion into other types of cancers, as well as developments in the areas of individualized vaccine design and manufacturing. Integration of whole genome and tumor sequencing with artificial intelligence is likely to increase the number of neoantigens identified for patients, while mRNA and other flexible vaccine platforms will allow the development of individualized vaccines in larger volumes.
In addition to that, personalized vaccines are expected to be increasingly used in conjunction with immunotherapies, especially immune checkpoint inhibitors. In addition, advances in biomarker development may facilitate patient selection for trials as well as improve the design of trials. The growing activity in North America, Europe, and Asia-Pacific shows that the field of personalized cancer vaccine development is becoming global. In summary, late-stage candidate development, the expansion of clinical trials, and the involvement of large pharma and biotech companies indicate that the personalized cancer vaccine space is becoming an increasingly important part of the changing cancer immunotherapy landscape.
1. RESEARCH METHODOLOGY
2. PERSONALIZED CANCER VACCINES: ADVANCING NEXT GENERATION CANCER IMMUNOTHERAPY
2.1 Approach To Cancer Vaccine Strategy
2.2 Cancer Vaccines - Current Progress & Challenges
3. MECHANISM UNDERLYING PERSONALIZED CANCER VACCINE EFFICACY
3.1 Role of Tumor Neoantigens & Human Leukocyte Antigen
3.2 Personalized Cancer Vaccine Working Mechanism
3.3 Genetic Polymorphism In Pharmacogenomics
3.4 Cancer Pharmacogenomics & Somatic Mutations
4. SIGNIFICANCE OF BIOMARKERS IN PERSONALIZED CANCER VACCINE DESIGN
4.1 Pharmacogenomic Biomarkers
4.2 Prognostic & Predictive Biomarkers
5. PERSONALIZED CANCER VACCINES CLINICAL TRIALS INSIGHT BY DEVELOPER, INDICATION & PHASE
6. PROVENGE – 1ST APPROVED PERSONALIZED CANCER VACCINE
6.1 Overview & Patent Insight
6.2 Pricing & Dosing Insight
7. CURRENT CLINICAL DEVELOPMENT & FUTURE COMMERCIALIZATION OUTLOOK
7.1 Current Market Development Scenario
7.2 Future Market Outlook
8. PERSONALIZED CANCER VACCINES CLINICAL TENDS & DEVELOPMENTS INSIGHT BY INDICATION
8.1 Melanoma
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Prostate Cancer
8.5 Gastrointestinal Cancers
8.6 Gynecological Cancers
8.7 Brain Tumor
8.8 Hematological Malignancies
9. PERSONALIZED CANCER VACCINES CLINICAL & MARKET INSIGHT BY REGION
9.1 US
9.2 EU
9.3 China
9.4 India
9.5 Australia
9.6 South Korea
9.7 Taiwan
9.8 UK
10. PERSONALIZED CANCER VACCINES PROPRIETARY DEVELOPMENT PLATFORMS
11. PERSONALIZED CANCER VACCINE MARKET DYNAMICS
11.1 Market Drivers & Opportunities
11.2 Market Challenges & Restraints
12. COMPETITIVE LANDSCAPE
12.1 BioNtech AG
12.2 CureVac AG
12.3 Evaxion Biotech
12.4 Geneos Therapeutics
12.5 Genentech
12.6 Merck
12.7 Moderna Therapeutics
12.8 NeoCura
12.9 Transgene
12.10 TuHURA Biosciences
2. PERSONALIZED CANCER VACCINES: ADVANCING NEXT GENERATION CANCER IMMUNOTHERAPY
2.1 Approach To Cancer Vaccine Strategy
2.2 Cancer Vaccines - Current Progress & Challenges
3. MECHANISM UNDERLYING PERSONALIZED CANCER VACCINE EFFICACY
3.1 Role of Tumor Neoantigens & Human Leukocyte Antigen
3.2 Personalized Cancer Vaccine Working Mechanism
3.3 Genetic Polymorphism In Pharmacogenomics
3.4 Cancer Pharmacogenomics & Somatic Mutations
4. SIGNIFICANCE OF BIOMARKERS IN PERSONALIZED CANCER VACCINE DESIGN
4.1 Pharmacogenomic Biomarkers
4.2 Prognostic & Predictive Biomarkers
5. PERSONALIZED CANCER VACCINES CLINICAL TRIALS INSIGHT BY DEVELOPER, INDICATION & PHASE
6. PROVENGE – 1ST APPROVED PERSONALIZED CANCER VACCINE
6.1 Overview & Patent Insight
6.2 Pricing & Dosing Insight
7. CURRENT CLINICAL DEVELOPMENT & FUTURE COMMERCIALIZATION OUTLOOK
7.1 Current Market Development Scenario
7.2 Future Market Outlook
8. PERSONALIZED CANCER VACCINES CLINICAL TENDS & DEVELOPMENTS INSIGHT BY INDICATION
8.1 Melanoma
8.2 Lung Cancer
8.3 Breast Cancer
8.4 Prostate Cancer
8.5 Gastrointestinal Cancers
8.6 Gynecological Cancers
8.7 Brain Tumor
8.8 Hematological Malignancies
9. PERSONALIZED CANCER VACCINES CLINICAL & MARKET INSIGHT BY REGION
9.1 US
9.2 EU
9.3 China
9.4 India
9.5 Australia
9.6 South Korea
9.7 Taiwan
9.8 UK
10. PERSONALIZED CANCER VACCINES PROPRIETARY DEVELOPMENT PLATFORMS
11. PERSONALIZED CANCER VACCINE MARKET DYNAMICS
11.1 Market Drivers & Opportunities
11.2 Market Challenges & Restraints
12. COMPETITIVE LANDSCAPE
12.1 BioNtech AG
12.2 CureVac AG
12.3 Evaxion Biotech
12.4 Geneos Therapeutics
12.5 Genentech
12.6 Merck
12.7 Moderna Therapeutics
12.8 NeoCura
12.9 Transgene
12.10 TuHURA Biosciences
LIST OF TABLES
Table 3-1: Comparison Of HLA/MHC Class I & Class II
Table 4-1: Prognostic & Predictive Biomarkers - Examples
Table 5-1: Personalized Cancer Vaccines By Developer, Indication & Phase
Table 3-1: Comparison Of HLA/MHC Class I & Class II
Table 4-1: Prognostic & Predictive Biomarkers - Examples
Table 5-1: Personalized Cancer Vaccines By Developer, Indication & Phase
LIST OF FIGURES
Figure 2-1: Cancer Vaccine Types
Figure 2-2: Advantages Of Targeting Neoantigens In Cancer Vaccine Development
Figure 3-1: Neoantigen–T-cell recognition
Figure 3-2: Personalized Cancer Vaccine - Mechanism
Figure 3-3: Demonstrating Genomic Polymorphism In Pharmacogenomics
Figure 3-4: Source of Pharmacological & Pharmacogenetic Variability
Figure 3-5: Tumor vs. Normal Genetic Profile
Figure 4-1: Biomarkers In Personalized Medicine
Figure 4-2: Pharmacogenomic Biomarkers In Cancer Vaccines
Figure 4-3: Prognostic vs Predictive Biomarkers
Figure 4-4: Roadmap For Developing Predictive Biomarkers
Figure 6-1: Provenge – Approval Year By Region
Figure 6-2: Provenge – Cost Per Unit & Supply (US$), August’2026
Figure 7-1: Global Personalized Cancer Vaccines Market - Future Outlook
Figure 8-1: KEYNOTE-942 Phase 2 (NCT03897881) Study – Initiation & Completion Year
Figure 8-2: INTerpath-001 Phase 3 (NCT05933577) Study – Initiation & Completion Year
Figure 8-3: KEYNOTE-D36 Phase 2 (NCT05309421) Study – Initiation & Completion Year
Figure 8-4: 18-279 Phase 1 (NCT03929029) Study – Initiation & Completion Year
Figure 8-5: KEYNOTE-603 Phase 1 (NCT03313778) Study – Initiation & Completion Year
Figure 8-6: V940-002 Phase 3 (NCT06077760) Study – Initiation & Completion Year
Figure 8-7: INTerpath-009 Phase 3 (NCT06623422) Study – Initiation & Completion Year
Figure 8-8: INTerpath-013 Phase 2 (NCT07221474) Study – Initiation & Completion Year
Figure 8-9: INTerpath-014 Phase 3 (NCT07513376) Study – Initiation & Completion Year
Figure 8-10: CHUV-DO-0022-LUNGVAC-2019 Phase 1 (NCT06077760) Study – Initiation & Completion Year
Figure 8-11: 202104143 Phase 2 (NCT04397003) Study – Initiation & Completion Year
Figure 8-12: MCC-20915 Phase 2 (NCT05325632) Study – Initiation & Completion Year
Figure 8-13: PNeoVCA Phase 1/2 (NCT05269381) Study – Initiation & Completion Year
Figure 8-14: MCC-22003 Phase 2 (NCT05751941) Study – Initiation & Completion Year
Figure 8-15: 2000035188 Phase 2 (NCT06100705) Study – Initiation & Completion Year
Figure 8-16: ProvONE Phase 2 (NCT06134232) Study – Initiation & Completion Year
Figure 8-17: FK-PC101-01 Phase 2 (NCT06636682) Study – Initiation & Completion Year
Figure 8-18: LEGION-100-2a Phase 2 (NCT06533644) Study – Initiation & Completion Year
Figure 8-19: 19-039 Phase 1 (NCT04161755) Study – Initiation & Completion Year
Figure 8-20: IMCODE003 Phase 2 (NCT05968326) Study – Initiation & Completion Year
Figure 8-21: GT-30 Phase 1/2 (NCT04251117) Study – Initiation & Completion Year
Figure 8-22: NCI-2016-00015 Phase 1 (NCT02600949) Study – Initiation & Completion Year
Figure 8-23: CHANT-191 Phase 1 (NCT04147078) Study – Initiation & Completion Year
Figure 8-24: QUILT 502 Phase 1/2 (NCT06253494) Study – Initiation & Completion Year
Figure 8-25: CIP2023-001 Phase 1 (NCT06366490) Study – Initiation & Completion Year
Figure 8-26: NCI-2024-00210 Phase 1 (NCT06342908) Study – Initiation & Completion Year
Figure 8-27: GT-20 Phase 1 (NCT04015700) Study – Initiation & Completion Year
Figure 8-28: 14-362 Phase 1 (NCT02287428) Study – Initiation & Completion Year
Figure 8-29: 17-1051 Phase 1 (NCT03219450) Study – Initiation & Completion Year
Figure 8-30: 17-353 Phase 1 (NCT03361852) Study – Initiation & Completion Year
Figure 8-31: 24-439 Phase 1 (NCT06799026) Study – Initiation & Completion Year
Figure 10-1: BioNTech - iNeST
Figure 10-2: BioVaxys - DPX & Haptenix Platforms
Figure 10-3: CureVac - proprietary mRNA technology
Figure 10-4: Evaxion –Proprietary Technologies
Figure 10-5: Geneos - GT-EPIC Platform
Figure 10-6: Moderna - mRNA Design Studio Features
Figure 10-7: myNEO Therapeutics - ImmunoEngine
Figure 10-8: Nouscom - Unnamed Technology
Figure 10-9: Nykode Therapeutics – Vaccibody Structure
Figure 10-10: Nykode Therapeutics – Vaccibody Mechanism Of Action
Figure 10-11: Transgene - myvac Platform
Figure 11-1: Global Personalized Cancer Vaccines Market - Drivers & Opportunities
Figure 11-2: Global Personalized Cancer Vaccines Market - Challenges & Restraints
Figure 2-1: Cancer Vaccine Types
Figure 2-2: Advantages Of Targeting Neoantigens In Cancer Vaccine Development
Figure 3-1: Neoantigen–T-cell recognition
Figure 3-2: Personalized Cancer Vaccine - Mechanism
Figure 3-3: Demonstrating Genomic Polymorphism In Pharmacogenomics
Figure 3-4: Source of Pharmacological & Pharmacogenetic Variability
Figure 3-5: Tumor vs. Normal Genetic Profile
Figure 4-1: Biomarkers In Personalized Medicine
Figure 4-2: Pharmacogenomic Biomarkers In Cancer Vaccines
Figure 4-3: Prognostic vs Predictive Biomarkers
Figure 4-4: Roadmap For Developing Predictive Biomarkers
Figure 6-1: Provenge – Approval Year By Region
Figure 6-2: Provenge – Cost Per Unit & Supply (US$), August’2026
Figure 7-1: Global Personalized Cancer Vaccines Market - Future Outlook
Figure 8-1: KEYNOTE-942 Phase 2 (NCT03897881) Study – Initiation & Completion Year
Figure 8-2: INTerpath-001 Phase 3 (NCT05933577) Study – Initiation & Completion Year
Figure 8-3: KEYNOTE-D36 Phase 2 (NCT05309421) Study – Initiation & Completion Year
Figure 8-4: 18-279 Phase 1 (NCT03929029) Study – Initiation & Completion Year
Figure 8-5: KEYNOTE-603 Phase 1 (NCT03313778) Study – Initiation & Completion Year
Figure 8-6: V940-002 Phase 3 (NCT06077760) Study – Initiation & Completion Year
Figure 8-7: INTerpath-009 Phase 3 (NCT06623422) Study – Initiation & Completion Year
Figure 8-8: INTerpath-013 Phase 2 (NCT07221474) Study – Initiation & Completion Year
Figure 8-9: INTerpath-014 Phase 3 (NCT07513376) Study – Initiation & Completion Year
Figure 8-10: CHUV-DO-0022-LUNGVAC-2019 Phase 1 (NCT06077760) Study – Initiation & Completion Year
Figure 8-11: 202104143 Phase 2 (NCT04397003) Study – Initiation & Completion Year
Figure 8-12: MCC-20915 Phase 2 (NCT05325632) Study – Initiation & Completion Year
Figure 8-13: PNeoVCA Phase 1/2 (NCT05269381) Study – Initiation & Completion Year
Figure 8-14: MCC-22003 Phase 2 (NCT05751941) Study – Initiation & Completion Year
Figure 8-15: 2000035188 Phase 2 (NCT06100705) Study – Initiation & Completion Year
Figure 8-16: ProvONE Phase 2 (NCT06134232) Study – Initiation & Completion Year
Figure 8-17: FK-PC101-01 Phase 2 (NCT06636682) Study – Initiation & Completion Year
Figure 8-18: LEGION-100-2a Phase 2 (NCT06533644) Study – Initiation & Completion Year
Figure 8-19: 19-039 Phase 1 (NCT04161755) Study – Initiation & Completion Year
Figure 8-20: IMCODE003 Phase 2 (NCT05968326) Study – Initiation & Completion Year
Figure 8-21: GT-30 Phase 1/2 (NCT04251117) Study – Initiation & Completion Year
Figure 8-22: NCI-2016-00015 Phase 1 (NCT02600949) Study – Initiation & Completion Year
Figure 8-23: CHANT-191 Phase 1 (NCT04147078) Study – Initiation & Completion Year
Figure 8-24: QUILT 502 Phase 1/2 (NCT06253494) Study – Initiation & Completion Year
Figure 8-25: CIP2023-001 Phase 1 (NCT06366490) Study – Initiation & Completion Year
Figure 8-26: NCI-2024-00210 Phase 1 (NCT06342908) Study – Initiation & Completion Year
Figure 8-27: GT-20 Phase 1 (NCT04015700) Study – Initiation & Completion Year
Figure 8-28: 14-362 Phase 1 (NCT02287428) Study – Initiation & Completion Year
Figure 8-29: 17-1051 Phase 1 (NCT03219450) Study – Initiation & Completion Year
Figure 8-30: 17-353 Phase 1 (NCT03361852) Study – Initiation & Completion Year
Figure 8-31: 24-439 Phase 1 (NCT06799026) Study – Initiation & Completion Year
Figure 10-1: BioNTech - iNeST
Figure 10-2: BioVaxys - DPX & Haptenix Platforms
Figure 10-3: CureVac - proprietary mRNA technology
Figure 10-4: Evaxion –Proprietary Technologies
Figure 10-5: Geneos - GT-EPIC Platform
Figure 10-6: Moderna - mRNA Design Studio Features
Figure 10-7: myNEO Therapeutics - ImmunoEngine
Figure 10-8: Nouscom - Unnamed Technology
Figure 10-9: Nykode Therapeutics – Vaccibody Structure
Figure 10-10: Nykode Therapeutics – Vaccibody Mechanism Of Action
Figure 10-11: Transgene - myvac Platform
Figure 11-1: Global Personalized Cancer Vaccines Market - Drivers & Opportunities
Figure 11-2: Global Personalized Cancer Vaccines Market - Challenges & Restraints
